Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

NCT07105098 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT07105098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07105098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Recruiting
Start date
August 11, 2025
Completion date
November 30, 2027
Enrollment
284 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia